a collection of information unless it contains a valid OMB control number.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10806866			
Filing Date		2004-03-22			
First Named Inventor Dimp		isey et al.			
Art Unit		2185			
Examiner Name Savia		a, Arpan P.			
Attorney Docket Number		AUS920040065US1			

				U.S.	PATENTS	Remove
		Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	5966538		1999-10-12	Granston et al.	
	2	5940618		1999-08-17	Blandy et al.	
	3	6189142	B1	2001-02-13	Johnston et al.	
	4	5768500		1998-06-16	Agrawal et al.	
	5	6026235		2000-02-15	Shaughnessy	
	6	5950003		1999-09-07	Kaneshiro et al.	
	7	6594820	B1	2003-07-15	Ungar	
f you wish	to ac	dd additional U.S. Pate	ent citatio	n information p	lease click the Add button.	Add

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10806866		
Filing Date		2004-03-22		
First Named Inventor	Dimpsey et al.			
Art Unit		2185		
Examiner Name	Savla	Savla, Arpan P.		
Attorney Docket Number		AUS920040065US1		

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ition	Name of Pate of cited Docu	entee or Applicant iment	Releva		Lines where ges or Relev	
	1	20020073406	A1	2002-0	6-13	Gove					
	2	20030066055	A1	2003-0	4-03	Spivey					
	3	20030131343	A1	2002-0	7-10	French et al.					
	4	20040268316	A1	2004-12	2-30	Fisher et al.					
If you wisi	h to a	dd additional U.S. Publi						d buttor	$\overline{}$		
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup> Country Code <sup>2</sup> i Kind Date Name of Patentee or Applicant of cited Document Passages or Reference or Pages Columns, Li where Relevant Passages or Reference or Pages Columns, Li where Relevant Passages or Reference or Pages Columns, Li where Relevant Passages or Reference or Pages Columns, Li where Relevant Passages or Reference or Pages Columns, Li where Relevant Pag						evant or Relevant	TA		
	1										
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	button	Add		
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Examiner Cite (Initials* No linclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposism, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.									T5	
	1										
If you wis	h to a	dd additional non-paten	t literatu	re docu	ment cit	lation informati	ion please click the	Add b	utton A	id	_

	Application Number		10806866	
INFORMATION DIGGS COURT	Filing Date		2004-03-22	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Dimp		psey et al.	
( Not for submission under 37 CFR 1.99)	Art Unit		2185	
,	Examiner Name Savla		la, Arpan P.	
	Attorney Docket Number		AUS920040065US1	

Examiner Signature		Date Considered	
*EXAMINER: Initial if	reference considered, whether or not citation is in conformation	nce with MPEP 609	Draw line through a

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Ninc Cotes of USPTO Patent Documents at invent USPTO\_GOV/ or MPEP 90104. 2 Enter office that issued the document, by the two-letter OW/IPPO Standard ST3.) 3 "For Jupanese patent document, the architecture of the patent office patent office patent document. A for office counter of the patent office paten

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10806866		
Filing Date		2004-03-22		
First Named Inventor	Dimpsey et al.			
Art Unit		2185		
Examiner Name	Savla, Arpan P.			
Attorney Docket Number		AUS920040065US1		

#### CERTIFICATION STATEMENT

Diagon con	37	CFR	1 97	and	1 98 to	make	the	appropriate	coloction/	e١

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(a)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of Information contained in the information disclosure statement was known to [2] any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) The 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) the statement of the control of

- See attached certification statement.
- Fee set forth in 37 CFR 1,17 (p) has been submitted herewith.
  - □ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Gerald H. Glanzman/	Date (YYYY-MM-DD)	2006-10-05					
Name/Print	Gerald H. Glanzman	Registration Number	25035					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application port to public insepticines or an issuand patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.